Chronix Biomedical welcomes moves to define new regulatory standards in liquid biopsy field

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (20 July 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, welcomes the recent moves to more clearly define US regulatory standards for the use of...

By | July 20th, 2016|Chronix news|0 Comments

Chronix Biomedical’s serum DNA assays can monitor disease activity and treatment response in multiple sclerosis

Chronix Biomedical

San Jose, California, April 6, 2010 – Chronix Biomedical today announced publication of a study that supports the utility of its serum DNA blood tests to predict clinical status and monitor disease activity and response to...

By | June 3rd, 2016|Chronix news|0 Comments

New study shows blood test detected cancer metastasis

Chronix Biomedical

RESEARCH BY CHRONIX BIOMEDICAL AND INSTITUTE OF VETERINARY MEDICINE GÖTTINGEN HIGHLIGHTS CELL-FREE DNA ANALYSIS FOR CANCER MINIMAL RESIDUAL DISEASE San Jose, CA and Göttingen, Germany—September 30, 2013—Researchers from the University Göttingen Institute of Veterinary Medicine...

By | June 1st, 2016|Chronix news|0 Comments

New test increases sensitivity of HPV detection in cancer

Newswise

Newswise — CHICAGO (May 30, 2014) – Researchers from Sanford Health and Chronix Biomedical today announced that results from a pilot study demonstrating the utility of a new cancer panel to detect previously undetected viral...

By | June 1st, 2016|Chronix news|0 Comments

Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response to immunotherapy

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (19 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces positive data from a blinded proof of concept clinical study, assessing the utility...

By | May 19th, 2016|Chronix news|0 Comments

Chronix Biomedical to present clinical data on its cell-free DNA approach as an early predictor of response to immunotherapy at the ASCO Annual Meeting

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (3 May, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today announces that it will present clinical data relating to its cell-free DNA copy number...

By | May 3rd, 2016|Chronix news|0 Comments

Changes in tumor cell-free DNA copy number instability (CNI) predict therapeutic response in metastatic cancers

Chronix Biomedical

San Jose, CA, USA and Göttingen, Germany (April 18, 2016) – Chronix Biomedical, Inc., a developer of blood-based molecular diagnostics, today presents positive data from a blinded proof of concept clinical study, assessing the utility...

By | April 18th, 2016|Chronix news|0 Comments